Cargando…
The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay
Histone deacetylase 3 (HDAC3) is a potential target for the treatment of human diseases such as cancers, diabetes, chronic inflammation and neurodegenerative diseases. Previously, we proposed a virtual screening (VS) pipeline named “Hypo1_FRED_SAHA-3” for the discovery of HDAC3 inhibitors (HDAC3Is)...
Autores principales: | Xia, Jie, Hu, Huabin, Xue, Wenjie, Wang, Xiang Simon, Wu, Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978667/ https://www.ncbi.nlm.nih.gov/pubmed/29464997 http://dx.doi.org/10.1080/14756366.2018.1437156 |
Ejemplares similares
-
A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors
por: Hu, Huabin, et al.
Publicado: (2017) -
Discovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays
por: Shen, Mingyun, et al.
Publicado: (2015) -
Discovery of human TyrRS inhibitors by structure-based virtual screening, structural optimization, and bioassays
por: Huang, Shenzhen, et al.
Publicado: (2019) -
Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays
por: Pang, Jin-ping, et al.
Publicado: (2022) -
Virtual screening of bioassay data
por: Schierz, Amanda C
Publicado: (2009)